Triple Negative Breast Cancer Clinical Trials in Birmingham, Alabama

4 studies are recruiting for triple negative breast cancer in Birmingham, Alabama right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

    The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabin…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Alabama Oncology, Birmingham, Alabama
    Locations
    372 in total
    Run by
    Gilead Sciences

    See if you can join NCT05633654 on ClinicalTrials.gov

  2. PRE-ISPY Phase I/II Oncology Platform Program

    PRE-ISPY Phase I/II (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed to evaluate single agents or combinations in locally advanced, incurable, or metastatic solid tumors and/or oligometastatic malignancy and/…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, Alabama
    Locations
    10 in total
    Run by
    QuantumLeap Healthcare Collaborative

    See if you can join NCT05868226 on ClinicalTrials.gov

  3. Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI)

    This clinical study will investigate the utility of Fludeoxyglucose (18F) fluoromisonidazole (FMISO), in patients diagnosed with triple negative breast cancer (stage II-IV disease), to monitor and predict the effect of immunotherapy. This is a parallel imaging study to current treatment strategies …

    Stage
    EARLY_Phase 1
    Ages
    18 to 75
    Site
    UAB, Birmingham, Alabama
    Run by
    University of Alabama at Birmingham

    See if you can join NCT04861077 on ClinicalTrials.gov

  4. Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

    The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [177Lu]Lu-NNS309 and the safety, dosimetry and imaging properties of [68Ga]Ga-NNS309 in patients aged ≥ 18 years with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), non-…

    Stage
    Phase 1
    Ages
    18 to 100
    Site
    Uni of Alabama at Birmingham, Birmingham, Alabama
    Locations
    29 in total
    Run by
    Novartis Pharmaceuticals

    See if you can join NCT06562192 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.